Passage Bio, a genetic medicines company developing AAV-delivered gene therapies for the treatment of rare monogenic central nervous system diseases, today announced that Jill Quigley, chief operating officer, will present at the Barclays Gene Editing & Gene Therapy Summit on Wednesday, November 13th, 2019 at 9:30 a.m. ET in New York, NY.
Our partner, Passage Bio, a genetic medicines company developing AAV-delivered gene therapies for the treatment of rare monogenic central nervous system diseases, today announced the appointment of Richard Morris as chief financial officer.
Dr. Jim Wilson is a guest today at Amicus’ 2019 Analyst Day which will highlight the portfolio of novel therapies for rare metabolic diseases.
Our partner, Amicus Therapeutics today announced upcoming presentations at the following medical and investor conferences in October 2019.
Passage Bio, a genetic medicines company developing AAV-delivered gene therapies for the treatment of rare monogenic central nervous system diseases, today announced the appointments of Gary Romano, M.D., Ph.D, as chief medical officer and Edgar (Chip) Cale, J.D., as general counsel.
Passage Bio, a genetic medicines company developing AAV-delivered gene therapies for the treatment of rare monogenic central nervous system (CNS) diseases, today announced that it has licensed a sixth gene therapy development program under its research, collaboration and license agreement with the University of Pennsylvania and its Gene Therapy Program (GTP). The license is for the clinical development of a potential treatment for patients with Charcot-Marie-Tooth Neuropathy Type 2A (CMT2A).
